Zschiedrich, M
Zschiedrich, M. multicenter ARPC5 Stage III study. The scholarly research examines whether rituximab, as well as the regular treatment with steroid-boli, qualified prospects to a better one-year kidney allograft function, set alongside the regular treatment only in individuals with severe T-cell mediated tubulointerstitial rejection and significant B-cell infiltrates within their biopsies. A complete of 180 […]